Blood Coagulants Market Research Report– Middle East & Africa forecast to 2027

Middle East & Africa Blood Coagulants Market Information, By Types (Coagulation Factor, others), Indication (Haemophilia, Surgery, other Bleeding Disorders) -Forecast till 2027

ID: MRFR/Pharma/2027-CR | July 2017 | Region: Global | 53 Pages         

Blood Coagulants Market Speak to Analyst Request a Free Sample

Middle East & Africa Blood Coagulants Market Overview


Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding. The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A  research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients


The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.


The Middle East & Africa blood coagulants market is expected to grow at the CAGR of 9.5% during the forecast period 2017-2023 


Figure- MEA blood coagulants market, by Country 2016 (%) MEA blood coagulants market


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors 


Research Methodology:


MEA blood coagulants market research


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 


Segmentation    


The Middle East & Africa blood coagulants market is segmented on the basis of types, indications, and by country.


On the basis of types, the Middle East & Africa blood coagulants market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.


On the basis of indication, the Middle East & Africa blood coagulants market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.


On the basis of country, the Middle East & Africa blood coagulants market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa. 


Regional Analysis


The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country. 


Key Findings:



  • Hemophilia segment dominates the market with nearly 45.5% share of the MEA market

  • MEA coagulation factor market is projected to reach about USD 141.68 million by 2023

  • MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016

  • UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023


Key Players for Middle East & Africa blood coagulants market


Some of the major players in Middle East & Africa blood coagulants market are: Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Middle East & Africa blood coagulants market is projected to grow at approximately 9.5% CAGR during the assessment period (2020-2027).

Middle East & Africa blood coagulants market is estimated to reach a valuation of approx. USD 141.68 MN by the end of 2023.

Rising funding from the private & public organizations, proliferation of healthcare insurance coverage, and awareness programs for bleeding disorders, are major tailwinds pushing the growth of the Middle East & Africa blood coagulants market.

Lack of R&D capabilities and awareness in most of the parts of developing and underdeveloped countries and presence of counterfeit drugs in the regions, are major growth impeder for the Middle East & Africa blood coagulants market.

Saudi Arabia holds the largest share in the Middle East & Africa blood coagulants market.

Pfizer Inc. (U.S.), Novo Nordisk AS (Denmark), Bayer AG (Germany), SOBI (Sweden), Shire (Republic of Ireland), CSL Limited (Australia), and Octapharma (Switzerland), are some of the top players operating in the Middle East & Africa blood coagulants market.